Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT04658472Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2021
- Primary completion
- Oct 2025
- Modality
- IgG Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Sanofi. Started Apr 2021; status: completed.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT04658472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04658472.